219530-19-5

Upstream product

• 100-39-0 benzyl bromide 
• 219530-29-7 1,4-anhydro-2-O-benzoyl-5-O-benzyl-3-O-(4-methoxybenzyl)-D-ribitol 
• 219530-25-3 5-O-benzyl-1,2-O-isopropylidene-3-O-(4-methoxybenzyl)-α-D-ribofuranose 
• 219530-27-5 3-O-(4-methoxybenzyl)-5-O-benzyl-D-ribitol 
• 219530-30-0 1,4-anhydro-5-O-benzyl-3-O-(4-methoxybenzyl)-D-ribitol 
• 2592-42-9 5-O-benzyl-1,2-O-isopropylidene-α-D-ribofuranose 
• 219530-31-1 1,4-anhydro-2,5-di-O-benzyl-3-O-(4-methoxybenzyl)-D-ribitol 

Relevant academic research and scientific papers

Synthesis of adenophostin analogues lacking the adenine moiety as novel potent IP3 receptor ligands: Some structural requirements for the significant activity of adenophostin a

1-O-Tetrahydrofuranyl-α-D-glucopyranose derivatives 5-8 were designed and synthesized as novel IP3 receptor ligands. The glycosidation reactions between fluoroglycosyl donor 23 and tetrahydrofuran derivatives 11-14 as glycosyl acceptors selectively gave the corresponding α-glycosides, which were converted into the target compounds 5-8 via the introduction of phosphate groups using the phosphoramidite method. Among these compounds, 1- O-tetrahydrofuranyl-α-D-glucopyranose trisphosphate derivatives 5 and 8 significantly inhibited the binding of [3H] IP3 to IP3 receptor from porcine cerebella, with IC50 values of 25 and 27 nM, respectively, which were comparable to the affinity of IP3 itself.